Eli Lilly’s latest experience really reduced the burden for those who participated; even too much, for some.
The North American pharmaceutical company Eli Lilly last week the results of its most recent experimental drug against obesity.
The retatrutide provided a weight loss from until 32,3 kg on average, as well as substantial pain relief from osteoarthritis in the first Phase 3 study – which was successful.
Lilly announced that retatrutide provided an average weight loss of 28.7% after 68 weeks at the highest dosagecompared to 2.1% in the placebo group participants.
The medicine reduced pain by an average of up to 75.8% and significantly improved physical functions, with more than 1 in 8 patients no longer experiencing any knee pain at the end of the study.
Retatrutide is presented as a triple agonist of the hormone receptors GIP, GLP-1 and glucagon; It is the first of its kind in adults with obesity or overweight and knee osteoarthritis.
At one point, the company reveals that the study was so successful that it led some people to stop the test “due to perceived excessive weight loss”.
In other words, as Axios highlights, this medicine proved to be so effective in clinical trials that It’s almost too effective for some people – those who gave up because they felt they were losing too much weight.
Eli Lilly does not reveal the number of people who dropped out of the study for this reason.
Impact: Lilly shares rose 1.6%.
